Researchers described EVG7, a novel glycopeptide antibiotic that prevents Clostridioides difficile recurrence while selectively sparing beneficial gut commensals. In preclinical models, EVG7 stopped C. difficile growth and preserved microbial populations linked to colonization resistance. Selective killing reduces the ecological disruption typical of broad‑spectrum antibiotics, a property that could lower recurrence rates and protect microbiome‑mediated functions. The molecule’s mechanism and preclinical safety profile position it as a potential therapeutic for acute CDI and for patients at high risk of recurrence. Clinical development plans and human safety data were not detailed in the report; developers will need to show translational microbiome benefits and clinical endpoints in human trials to validate preclinical promise.